Donald Degolyer Sells 15,481 Shares of Emergent Biosolutions (NYSE:EBS) Stock

Key Points

• Director Donald Degolyer sold 15,481 shares at an average price of $8.40 on May 1 under a pre-arranged Rule 10b5-1 plan, trimming his position by 10.66% to 129,721 shares valued at about $1.09M.
• Emergent beat quarterly estimates, reporting EPS of $0.21 versus a consensus loss of ($0.25) and revenue of $156.1M compared with $145M expected.
• Shares trade near $8.51 with a market cap of $439M and a 52-week range of $4.71–$14.06; institutional ownership is high (78.4%) and analysts have a consensus rating of Hold with a $12 average price target.

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Donald Degolyer sold 15,481 shares of the company's stock in a transaction on Friday, May 1st. The stock was sold at an average price of $8.40, for a total value of $130,040.40. Following the sale, the director owned 129,721 shares of the company's stock, valued at approximately $1,089,656.40. This represents a 10.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Up 0.4%

NYSE EBS traded up $0.04 on Monday, hitting $8.51. The stock had a trading volume of 839,196 shares, compared to its average volume of 878,575. The business's fifty day moving average price is $8.54 and its 200 day moving average price is $10.30. The stock has a market cap of $439.23 million, a price-to-earnings ratio of -30.38 and a beta of 2.33. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.29 and a quick ratio of 2.08. Emergent Biosolutions Inc. has a 52-week low of $4.71 and a 52-week high of $14.06.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of ($0.25) by $0.46. The firm had revenue of $156.10 million during the quarter, compared to analyst estimates of $145.00 million. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.

Hedge Funds Weigh In On Emergent Biosolutions

Several hedge funds have recently made changes to their positions in EBS. Silver Oak Securities Incorporated acquired a new position in shares of Emergent Biosolutions in the third quarter valued at about $941,000. Allianz Asset Management GmbH lifted its holdings in shares of Emergent Biosolutions by 149.0% during the third quarter. Allianz Asset Management GmbH now owns 279,807 shares of the biopharmaceutical company's stock worth $2,468,000 after purchasing an additional 167,423 shares during the period. Federated Hermes Inc. lifted its holdings in shares of Emergent Biosolutions by 43.6% during the third quarter. Federated Hermes Inc. now owns 401,258 shares of the biopharmaceutical company's stock worth $3,539,000 after purchasing an additional 121,789 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in Emergent Biosolutions in the third quarter valued at approximately $393,000. Finally, New York State Common Retirement Fund increased its holdings in Emergent Biosolutions by 32.6% in the 3rd quarter. New York State Common Retirement Fund now owns 522,004 shares of the biopharmaceutical company's stock worth $4,604,000 after buying an additional 128,429 shares during the period. 78.40% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on EBS. Wall Street Zen downgraded Emergent Biosolutions from a "buy" rating to a "hold" rating in a report on Sunday, March 8th. HC Wainwright cut their price objective on shares of Emergent Biosolutions from $15.00 to $12.00 and set a "buy" rating on the stock in a report on Monday, March 9th. Finally, Weiss Ratings lowered shares of Emergent Biosolutions from a "sell (d+)" rating to a "sell (d)" rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $12.00.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.